PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman

October 5, 2020 10:02:30

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which includes a focus on “breakthrough treatments of depression” through the development of government-approved ketamine compounds and a network of treatment clinics. The company’s dual mission is to develop the next generation of novel psychedelic treatments and delivery systems and help those suffering from mental health disorders in its own ketamine-based clinics.

To view the full press release, visit https://ibn.fm/JIsbw

About Champignon Brands Inc.

Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com